Session Summary:
The ongoing COVID-19 pandemic has had significant global impact on cardiothoracic transplantation. The ISHLT COVID-19 webinar will discuss various aspects of the pandemic on heart and lung transplantation using a case-based approach. Topics include infectivity of SAR-CoV-2, management of wait listed patients infected with or exposed to SARS-CoV-2, summary of recent COVID-19 therapeutic trials and implications for transplant recipients, and lung transplant evaluation and listing criteria for COVID-19 related respiratory failure. Faculty will be available for a live Q&A session.
Moderators: Fernanda Silveira, MD, and Stephan Ensminger, MD, DPhil
Welcome and Program Panel Introduction
Fernanda Silveira, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Case Presentation: Patient on the Waitlist with Persistent Positive PCR
Jonathan Hand, MD, Ochsner Medical Center, New Orleans, LA, USA
Infectivity of SARS-CoV-2
Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada
This talk will discuss the infectiousness and detection of SARS-CoV-2 with respect to incubation period as well as time and severity of illness with a focus on data regarding viral cultures and PCR results.
Waitlist Management of Patients Infected With or Exposed To SARS-CoV-2
Enrico Ammirati, MD, PhD, Asst Grande Ospedale Metropolitano Niguarda, Milan, Italy
The infectiousness of SARS-CoV-2 is of particular clinical relevance in waitlisted candidates with COVID-19 who resolve symptoms of infection but continue to have positive PCRs and the timing of waitlist activation. Additionally, the speaker will discuss inactivation of patients on the waitlist with known exposure to a confirmed case of COVID-19.
Case Presentation: Transplant Recipient With COVID-19
Paola Morejon Barragan, MD, Instituto Argentino de Diagnostico y Tratamiento, Buenos Aires, Argentina
COVID-19 Targeted Therapies
Robin Avery, MD, Johns Hopkins Hospital, Baltimore, MD, USA
This presentation will focus on clinical trials for management of COVID-19 and take home messages from these trials that are pertinent to transplant recipients, as well as recommendations for immunosuppression management (especially if a patient receives dexamethasone).
Case Presentation: Non-Transplant Patient with COVID-19 Related Respiratory Failure
Caroline Patterson, BMBS BMedSci MD, Royal Papworth Hospital, Cambridge, United Kingdom
Lung Transplant for COVID-19
Konrad Hoetzenecker, MD, Medical University of Vienna, Vienna, Austria
This talk will discuss evaluation and listing criteria for patients with COVID-19 related ARDS as well as surgical challenges and post-transplant immunosuppression
Q & A Segment with All Faculty
Led by Stephan Ensminger, MD, DPhil, University of Lubeck, Lubeck, Germany
ISHLT COVID-19 Task Force Update
Saima Aslam, MD, MS, UCSD, San Diego, CA, USA
COVID-19 Task Force Chair
ISHLT Announcements
Greg Schultz, CEO, ISHLT, Addison, TX, USA
ISHLTv Webinar: Update on COVID-19 and Challenges in Cardiothoracic Transplantation Enduring Material
RECORDED on November 18, 2020
Release Date: November 20, 2020
Expiration Date: November 20, 2021
On-line
Acknowledgement of Financial and/or In-Kind Commercial Support
No financial or in-kind commercial support was received for this educational activity.
Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Physicians
Accreditation Statement - The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement - ISHLT designates this live virtual activity for 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NursesIn support of improving patient care, this activity has been planned and implemented by Amedco LLC and the International Society for Heart & Lung Transplantation. Amedco LLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this live virtual activity for 1.50 contact hours for nurses.
Transplant Coordinators
As a designated Approved Provider by the American Board for Transplant Certification (ABTC), the International Society for Heart and Lung Transplantation grants up to 1.50 Category 1 Continuing Education Points for Transplant Coordinators (CEPTCs) for this offering. CEPTC Approval Number: 221-18.
Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.
Objectives - After attending this program, you should be able to:
1. Discuss various aspects the the pandemic on heart and lung transplantation using a case-based approach.
2. Discuss inactivation of patients on the waitlist with known exposure to a confirmed case of COVID-19.
3. Discuss clinical trials for management of COVID-19.
4. Discuss recommendations for immunosuppression management.
5. Discuss evaluation and listing criteria for patients with COVID-19 related ARDS as well as surgical challenges and post transplant immunosuppression.
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-‐6.2, 6.5)
All individuals in a position to control the content of CE are listed below.
First Name |
Last Name |
Role in Activity |
Commercial Interest:Relationship |
Enrico |
Ammirati |
Speaker |
No disclosures |
Saima |
Aslam |
Speaker |
No disclosures |
Robin |
Avery |
Speaker |
Aicuris, Research Grant Site Principal Investigator; Astellas, Research Grant Site Principal Investigator; Chimerix, Research Grant Site Principal Investigator; Merck, Research Grant Site Principal Investigator; Oxford Immunotec, Research Grant Site Principal Investigator; Qiagen, Research Grant Site Principal Investigator; Takeda/Shire Research Grant Site Principal Investigator. |
Jenny |
Clark |
Planner |
No Disclosures |
Stephen |
Ensminger |
Moderator |
No Disclosures |
Jonathan |
Hand |
Speaker |
|
Konrad |
Hoetzennecker |
Speaker |
No Disclosures |
Shahid |
Husain |
Speaker |
No Disclosures |
Paloa |
Moregjon Barragan |
Speaker |
No Disclosures |
Sheryl |
Morgan |
CE Coordinator |
No Disclosures |
Susie |
Newton |
Planner |
No Disclosures |
Caroline |
Patterson |
Speaker |
No Disclosures |
Greg |
Schultz |
Planner, ISHLT CEO |
No Disclosures |
Fernanda |
Silveria |
Moderator, Speaker |
Gilead, Research Grant Site Principal Investigator; Ansun, Research Grant Site Principal Investigator; Novartis, Research Grant Site Principal Investigator; Qiagen, Research Grant Site Principal Investigator; Shire, Research Grant Site Principal Investigator. |
How to Get Your Certificate
Questions? Email Certificate@AmedcoEmail.com
You must be logged in and own this session in order to post comments.
ISHLTv Webinar: Update on COVID-19 and Challenges in Cardiothoracic Transplantation Enduring Material
RECORDED on November 18, 2020
Release Date: November 20, 2020
Expiration Date: November 20, 2021
On-line
Acknowledgement of Financial and/or In-Kind Commercial Support
No financial or in-kind commercial support was received for this educational activity.
Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Physicians
Accreditation Statement - The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement - ISHLT designates this live virtual activity for 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NursesIn support of improving patient care, this activity has been planned and implemented by Amedco LLC and the International Society for Heart & Lung Transplantation. Amedco LLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this live virtual activity for 1.50 contact hours for nurses.
Transplant Coordinators
As a designated Approved Provider by the American Board for Transplant Certification (ABTC), the International Society for Heart and Lung Transplantation grants up to 1.50 Category 1 Continuing Education Points for Transplant Coordinators (CEPTCs) for this offering. CEPTC Approval Number: 221-18.
Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.
Objectives - After attending this program, you should be able to:
1. Discuss various aspects the the pandemic on heart and lung transplantation using a case-based approach.
2. Discuss inactivation of patients on the waitlist with known exposure to a confirmed case of COVID-19.
3. Discuss clinical trials for management of COVID-19.
4. Discuss recommendations for immunosuppression management.
5. Discuss evaluation and listing criteria for patients with COVID-19 related ARDS as well as surgical challenges and post transplant immunosuppression.
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-‐6.2, 6.5)
All individuals in a position to control the content of CE are listed below.
First Name |
Last Name |
Role in Activity |
Commercial Interest:Relationship |
Enrico |
Ammirati |
Speaker |
No disclosures |
Saima |
Aslam |
Speaker |
No disclosures |
Robin |
Avery |
Speaker |
Aicuris, Research Grant Site Principal Investigator; Astellas, Research Grant Site Principal Investigator; Chimerix, Research Grant Site Principal Investigator; Merck, Research Grant Site Principal Investigator; Oxford Immunotec, Research Grant Site Principal Investigator; Qiagen, Research Grant Site Principal Investigator; Takeda/Shire Research Grant Site Principal Investigator. |
Jenny |
Clark |
Planner |
No Disclosures |
Stephen |
Ensminger |
Moderator |
No Disclosures |
Jonathan |
Hand |
Speaker |
|
Konrad |
Hoetzennecker |
Speaker |
No Disclosures |
Shahid |
Husain |
Speaker |
No Disclosures |
Paloa |
Moregjon Barragan |
Speaker |
No Disclosures |
Sheryl |
Morgan |
CE Coordinator |
No Disclosures |
Susie |
Newton |
Planner |
No Disclosures |
Caroline |
Patterson |
Speaker |
No Disclosures |
Greg |
Schultz |
Planner, ISHLT CEO |
No Disclosures |
Fernanda |
Silveria |
Moderator, Speaker |
Gilead, Research Grant Site Principal Investigator; Ansun, Research Grant Site Principal Investigator; Novartis, Research Grant Site Principal Investigator; Qiagen, Research Grant Site Principal Investigator; Shire, Research Grant Site Principal Investigator. |
How to Get Your Certificate
Questions? Email Certificate@AmedcoEmail.com
Item | Price | Remove |
---|